CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 154 enrolled
Drug / intervention
Levetiracetamdrug
Likely dose
Levetiracetam 250 mg or 500 mg tablets, oral useAI-extracted
Key inclusion· 3
  • ✓Completed the Week 16 evaluation period of the N165 parent clinical trial of L059
  • ✓Patient or parent/guardian wishes to continue treatment with L059 and enter the follow-up study
  • ✓Investigator determines that continued levetiracetam treatment is medically necessary
Key exclusion· 3
  • ✕Did not participate in the N165 parent clinical trial of L059
  • ✕Participated in N165 but unwilling to continue on the same medication in the follow-up study
  • ✕Non-compliant with the N165 parent protocol during the study

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00160615
NCT00160615Phase 3Completed
CompareCT.gov

Follow-up Study of L059 (Levetiracetam) in Epileptic Patients With Partial Onset Seizures by Open Label Method

UCB Japan Co. Ltd.·interventional·Posted Sep 12, 2005·Updated Jun 10, 2019

In Brief

A Phase 3 clinical trial evaluating Levetiracetam for Epilepsy, Partial. Completed, enrolled 154 participants.

Detailed Summary

The safety and efficacy of L059 was evaluated in patients who completed "N165 Clinical Trial of L059". They received L059 at a daily dose from 1,000 mg to 3,000 mg in addition to their standard concomitant AEDs

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsEpilepsy, Partial
Countries--
Collaborators--

Timeline

Phase 3CompletedFinished
20022003200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedSep 12, 2005
Enrollment StartSep 12, 2001
Primary CompletionJan 17, 2007
TodayJul 2, 2026
Enrollment to primary: 5.3 yearsPosted 20.8 years ago

Interventions

Levetiracetamdrug

* Pharmaceutical form: Film-coating tablets * Concentration: 250 mg/ 500 mg * Route of administration: oral use